People in the News: Sinil Kim

Premium

Mirna Therapeutics has named Sinil Kim as its chief medical officer.

In this role, Kim will be responsible for the clinical development of Mirna’s phase I cancer drug MRX34, as well as other compounds in the firm’s pipeline, Mirna said.

Kim was most recently a senior director at Pfizer, serving as global clinical lead for two renal cancer drug programs. Before that, he was director of clinical oncology at Bristol-Myers Squibb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

The New York Times examines ethics and China's push to lead biomedical research.

At her blog, Sally Rockey dives into National Institutes of Health funding data.

In PNAS this week: ancestry and admixture in Brazilians, characterization of novel double-stranded RNA mycovirus, and more.

Researchers report that what scents someone picks up can reflect their complement of immune genes.